Achillion Pharma (ACHN) Misses Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq leads Wall St higher as Nvidia eases AI growth concerns
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil prices rise as investors weigh lack of progress in Middle East negotiations
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Revolution Medicines prices RASONQUE at $39,800 per month
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
Data Could Lead to Achillion Pharmaceuticals (ACHN) Takeover By Year End - Analyst
March 6, 2015 1:32 PM ESTWilliam Blair analyst Y. Katherine Xu offered some interesting commentary on Achillion Pharmaceuticals (NASDAQ: ACHN) after the company's "uneventful" fourth quarter report. While keeping her Market Perform rating and lowering her price target to $14.00 (from $15.00), Xu highlighted that Achillion intends to initiate three different combination studies in the treatment of hepatitis C virus (HCV) during 2015 to... More
